We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Doximity (DOCS) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
Doximity (DOCS - Free Report) closed the most recent trading day at $73.60, moving +1.28% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.48%. At the same time, the Dow added 0.27%, and the tech-heavy Nasdaq gained 0.94%.
The stock of medical social networking site has risen by 12.91% in the past month, leading the Medical sector's gain of 1.09% and the S&P 500's gain of 2.46%.
Analysts and investors alike will be keeping a close eye on the performance of Doximity in its upcoming earnings disclosure. The company is expected to report EPS of $0.38, up 26.67% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $157.73 million, up 15.27% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.5 per share and a revenue of $632.56 million, indicating changes of +5.63% and +10.9%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Doximity is currently a Zacks Rank #3 (Hold).
In terms of valuation, Doximity is presently being traded at a Forward P/E ratio of 48.38. This valuation marks a premium compared to its industry average Forward P/E of 38.89.
We can also see that DOCS currently has a PEG ratio of 3.52. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 3.28.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 68, finds itself in the top 28% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Doximity (DOCS) Exceeds Market Returns: Some Facts to Consider
Doximity (DOCS - Free Report) closed the most recent trading day at $73.60, moving +1.28% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.48%. At the same time, the Dow added 0.27%, and the tech-heavy Nasdaq gained 0.94%.
The stock of medical social networking site has risen by 12.91% in the past month, leading the Medical sector's gain of 1.09% and the S&P 500's gain of 2.46%.
Analysts and investors alike will be keeping a close eye on the performance of Doximity in its upcoming earnings disclosure. The company is expected to report EPS of $0.38, up 26.67% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $157.73 million, up 15.27% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.5 per share and a revenue of $632.56 million, indicating changes of +5.63% and +10.9%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Doximity. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Doximity is currently a Zacks Rank #3 (Hold).
In terms of valuation, Doximity is presently being traded at a Forward P/E ratio of 48.38. This valuation marks a premium compared to its industry average Forward P/E of 38.89.
We can also see that DOCS currently has a PEG ratio of 3.52. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Medical Info Systems industry was having an average PEG ratio of 3.28.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 68, finds itself in the top 28% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.